#1
|
||||
|
||||
íîâîñòè ñ ACC
Ïîÿâèëèñü ïîëóãîäîâûå äàííûå èç ABSORB:[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ñ ìîåé òî÷êè çðåíèÿ, âûãëÿäÿò íåñêîëüêî ðàçî÷àðóþùå - MACE 3.3% ÷åðåç ïîëãîäà ó èäåàëüíûõ áîëüíûõ - ìíîãîâàòî.
À âîò ðåçóëüòàòû SPIRIT 3 - ðàäóþò: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ëó÷øå, ÷åì ðåçóëüòàòû SIRIUS íà òîò ìîìåíò, êîãäà ìû î÷åíü ðåçêî âçÿëèñü çà ïîêðûòûå ñòåíòû. Ó÷èòûâàÿ ïîòðÿñàþùóþ ïëàòôîðìó ñ ñàìûì íèçêèì ïðîôèëåì - ìîæåò ñòàòü ëó÷øèì èç èìåþùèõñÿ íà ðûíêå. Êàêèå ñîîáðàæåíèÿ ó êîëëåã? |
#2
|
|||
|
|||
Äà, ðåçóëüòàòû îáíàäåæèâàþùèå.
 ðåàëå Èêñàåíñû â Ðîñèèè èìåþòñÿ? |
#3
|
||||
|
||||
Öèòàòà:
|
#4
|
||||
|
||||
Óâàæàåìûå êîëëåãè-èíòåðâåíöèîíèñòû,
Êòî íå ìîæåò äîæäàòüñÿ íà ACC îãëàøåíèÿ ðåçóëüòàòîâ COURAGE: PCI vs optimal medical therapy for stable coronary artery disease ìîãóò ïîñìîòðåòü èõ â ñåãîäíÿøíåé ïóáëèêàöèè íà ñàéòå NEJM [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] êîìó íå õî÷åòñÿ ÷èòàòü ïîëíîñòüþ, òî âîò ðåçóëüòàòû è âûâîäû Results There were 211 primary events in the PCI group and 202 events in the medical-therapy group. The 4.6-year cumulative primary-event rates were 19.0% in the PCI group and 18.5% in the medical-therapy group (hazard ratio for the PCI group, 1.05; 95% confidence interval [CI], 0.87 to 1.27; P=0.62). There were no significant differences between the PCI group and the medical-therapy group in the composite of death, myocardial infarction, and stroke (20.0% vs. 19.5%; hazard ratio, 1.05; 95% CI, 0.87 to 1.27; P=0.62); hospitalization for acute coronary syndrome (12.4% vs. 11.8%; hazard ratio, 1.07; 95% CI, 0.84 to 1.37; P=0.56); or myocardial infarction (13.2% vs. 12.3%; hazard ratio, 1.13; 95% CI, 0.89 to 1.43; P=0.33). Conclusions As an initial management strategy in patients with stable coronary artery disease, PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events when added to optimal medical therapy. Ðåäàêöèîííûé êîììåíòàðèé ê íåìó: Does Preventive PCI Work? Judith S. Hochman, M.D., and P. Gabriel Steg, M.D. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#5
|
|||
|
|||
èññëåäîâàíèå áåçóñëîâíî çàñëóæèâàþùåå âíèìàíèå. Îäíàêî äëÿ ìåíÿ íå ñîâñåì ïîíÿòíî çà÷åì â ãðóïïó PCI íóæíî áûëî âêëþ÷àòü ïàöèåíòîâ "Did not undergo PCI" êîëè÷åñòâîì 46 ÷åë. è "had a leasion that could not be dilated" êîëè÷åñòâîì 27 ÷åë. - èòîãî 73 ÷åë, ÷òî ñîñòàâëÿåò ~6,4%!!! À òàêæå íå ïîíÿòíî, äëÿ ÷åãî â ìåäèêàìåíòîçíóþ ãðóïïó áûëè âêëþ÷åíû ïàöèåíòû ñ ðàíåå âûïîëíåííûìè ÀÊØ è PCI îáùèì êîëè÷åñòâîì 309 ÷åë (27,2%)!!!
|
#7
|
|||
|
|||
"In 2004, more than 1 million coronary stent procedures were performed in the
United States and recent registry data indicate that approximately 85% of all PCI procedures are undertaken electively in patients with stable coronary artery disease" Ìíå êàæåòñÿ, ÷òî îáñóæäåíèå COURAGE íåîáõîäèìî ïðîäîëæèòü îòäåëüíî â âèäó åãî ïðèíöèïèàëüíîé âàæíîñòè: 1. èññëåäîâàíèå ïðàêòè÷åñêè "õîðîíèò" òàêòèêó "ïîòâåðæäàåì èøåìèþ è äàëåå îòïðàâëÿåì ïàöèåíòà ñî ñòàáèëüíîé ñòåíîêàðäèåé íà ÒÁÊÀ" 2. ñêîðåå âñåãî, ÒÁÊÀ ïðè ñòàáèëüíîé àòåðîñêëåðîòè÷åñêîé áëÿøêå ïðèíîñèò ñêîðåå âðåä, ÷åì ïîëüçó. 3. ïðåäèêòîðû ðàçðûâà ñòàáèëüíîé àðòåðîñêëåðîòè÷åñêîé áëÿøêè ìîãóò áûòü ïîëåçíû ïðè âûáîðå òàêòèêè âåäåíèÿ (ÒÁÊÀ/ÀÊØ vs ìåäèêàìåíòîçíîå ëå÷åíèå) |
|
#8
|
||||
|
||||
As expected NO benefit from PCI if used as primary therapy for chronic CAD. PCI is indicated ONLY as palliative Tx if medical treatment failed. If the patient is high risk (3v, LM, low EF) he needs CABG, not PCI.
|
#9
|
||||
|
||||
Öèòàòà:
|
#10
|
||||
|
||||
Òî, ÷òî íóæíî áûòü îñòîðîæíûì è ýìïèðè÷åñêèõ óìîçàêëþ÷åíèÿõ - ýòî ÷èñòàÿ ïðàâäà. Íà ïðîòÿæåíèè ïîñëåäíèõ 10 ëåò íå áûëî íè îäíîãî èññëåäîâàíèÿ, êîòîðîå ïîêàçàëî áû ïðåèìóùåñòâî PCI+OMT ïåðåä OMT (optimal medical therapy), íå ñìîòðÿ íà ýòîãî 80% ïðîöåäóð â ÑØÀ (ìåíüøå â Êàíàäå) âûïîëíÿåòñÿ äëÿ èìåííî ýòîé ãðóïïû ïàöèåíòîâ. Ìû çíàåì, ÷òî ïîêðûòûå ñòåíòû íå ëó÷øå, à ñêîðåå âñåãî õóæå îáû÷íûõ, è âñå ðàâíî 70% ñòåíòèðîâàíèé âûïîëíÿåòñÿ èìåííî èìè. Ëþáîå èññëåäîâàíèå èìååò ñâîè ïðîáëåìû, íî ñóòü EBM êàê ðàç è çàêëþ÷àåòñÿ â òîì, ÷òîáû èñïîëüçîâàòü â êëèíè÷ñåêîé ïðàêòèêå BEST AVAILABLE CLINICAL EVIDENCE. Òî, ÷òî êàæåòñÿ èíòóèòèâíî ïðàâèëüíûì, íå âñåãäà îêàçûâàåòñÿ òàêîâûì íà ïðàêòèêå. Íà ýòîì ÀÑÑ áûëî ìàññà ïðèìåðîâ. Óïîìÿíó õîòÿ áû òîöåòðàïèä (ïðåïàðàò, ïîâûøàþùèé HDL).
Èññëåäîâàòåëè, ïðîâîäèâøèå COURAGE çàñëóæèâàþò ñàìûõ âûñîêèõ ïîõâàë. Èì óäàëîñü äîáèòüñÿ ïðåêðàñíûõ ðåçóëüòàòîâ OMT. Ïðè ýòîì äàæå êëàññè÷åñêèé àðãóìåíò î ëó÷øåì ñèìïòîìàòè÷ñåêîì êîíòðîëå â ýòîì èññëåäîâàíèè áûë âåñüìà ñëàá. Ñèìïòîìû áûëè ïðàêòè÷åñêè îäèíàêîâû â îáåèõ ãðóïïàõ. Íà äèñêóññèè, ñîñòîÿâøåéñÿ ïîñëå ïðåäñòàâëåíèÿ ðåçóëüòàòîâ ñåãîäíÿ óòðîì, ñòîðîííèêè PCI íå ñìîãëè ïðèâåñòè ñêîëüêî-íèáóäü óáåäèòåëüíûõ äîâîäîâ, êðîìå "æåëàíèÿ ïàöèåíòîâ ïîëó÷èòü ñòåíò". Åñëè ïðî÷èòàòü ïðîòîêîë èññëåäîâàíèÿ, òî íóæíî îáðàòèòü âíèìàíèå íà òî, ÷òî ïàöèåíòû ðàíäîìèçèðîâàëèñü ÏÎÑËÅ àíãèîãðàôèè. Ïàöèåíòû ñ LM, 3v, ñíèæåííîé ôðàêöèåé âûáðîñà ïîøëè íà ðåâàñêóëÿðèçàöèþ, ïðåèìóùåñòâåííî øóíòèðîâàíèå. Êðîìå ýòîãî íèêòî íå áóäåò îñïàðèâàòü ïîëüçó ïåðâè÷íîãî PCI â ëå÷åíèè ACS âûñîêîãî ðèñêà è STEMI, åñëè òðîìáîëèòèêè íå ñìîãëè äàòü â ïåðâûé ÷àñ ïîñëå íà÷àëà ñèìïòîìîâ, òàê ÷òî çàêðûâàòü cath lab åùå ïðåæäåâðåìåííî , îäíàêî êàê ÿ óæå ìíîãî ðàç ãîâîðèë, íóæíî ñîñðåäîòî÷èòü óñèëèÿ ñëåäóåò èìåííî íà îñòðûé ïàöèåíòàõ (åñëè âîçìîæíî ñäåëàòü ñðàçó) è òåõ, êòî íå îòâåòèë íà òðîìáîëèòèêè, èëè õîòÿ áû äëÿ íà÷àëà ñäåëàòü òàê, ÷òîáû ýòè ñàìûå òðîìáîëèòèêè áûëè äîñòóïíû âñåì ïàöåíòàì ñ èíôàðêòîì â ïåðâûå ÷àñû PS. The difference between fiction and reality is that fiction has to make sense... |
#11
|
||||
|
||||
Öèòàòà:
|
#12
|
||||
|
||||
Âòîðîé âîïðîñ.  îáåèõ ãðóïïàõ ïðèìåðíî ó 25% áîëüíûõ â àíàìíåçå áûëà PCI. Åñòü ëè äàííûå, êàêîé ñîñóä ó ýòîé êàòåãîðèè áîëüíûõ áûë ñèìïòîì-ñâÿçàííûì ïîñëå ÊÀÃ, ïåðåä ðàíäîìèçàöèåé, òîò æå ñàìûé èëè äðóãîé? Áûëè ëè ýòè äàííûå ñîïîñòàâèìû â îáåèõ ãðóïïàõ? Ñ ìîåé òî÷êè çðåíèÿ âàæíûé ìîìåíò, ÷òî ÿâèëîñü ïðè÷èíîé ðåöèäèâà áîëåé, ðåñòåíîç èëè àòåðîñêëåðîç â äðóãîì ìåñòå. Î÷åâèäíî, ÷òî ïðîãíîç ó òàêèõ áîëüíûõ ðàçíûé.
|
#13
|
||||
|
||||
Êðîìå ýòîãî èíòåðåñíû òàêæå ðåçóëüòàòû îòñóòñòâèÿ ïîëüçû îò PET äëÿ ïîèñêà viability.
Èãîðü, ïàöèåíòàì ñî ñòåíîêàðäèåé, îñîáåííî âûðàæåííîé, âñå-ðàâíî íóæíî ñìîòðåòü àíàòîìèþ è îöåíèâàòü ñèñòîëè÷åñêóþ ôóíêöèþ Äëÿ ýòîãî ïðåêðàñíî ïîäõîäèò ECHO, SPECT è CT Angio. Ýòî ïðåêðàñíî ïîçâîëèò âûäåëèòü ïàöèåíòîâ, êîòîðûì ïîêàçàíà õèðóðãèÿ. Ïîñëå ýòîãî îïòèìèçèðîâàòü ëåêàðñòâà è åñëè ÷åðåç íåñêîëüêî ìåñÿöåâ ïàöèåíò âñå ðàâíî çíà÷èòåëüíî ëèìèòèðîâàí, âûïîëíÿòü ïàëèàòèâíóþ àíãèîïëàñòèêó. Diagnostic cath will be the thing of the past very soon I hope. |
#14
|
||||
|
||||
Òðåòèé âîïðîñ. Áûëà ëè êîíñåðâàòèâíàÿ òåðàïèÿ â äâóõ èññëåäóåìûõ ãðóïïûõ ñõîäíà äî ðàíäîìèçàöèè? Î÷åâèäíî, ÷òî åñëè íåêîìó ïàöèåíòó ÈÁÑ äëÿ ñòàáèëèçàöèè òðåáóåòñÿ áîëåå ìîùíàÿ òåðàïèÿ, òî è îæèäàòü äåñòàáèëèçàöèè ó íåãî ìîæíî îæèäàòü ñêîðåå.  ñðåäíåì, êîíå÷íî.
|
#15
|
||||
|
||||
Äîñòîâåííî çíàòü ÷òî áûëî ïðè÷èíîé áîëåé íåâîçìîæíî. Ìîæíî òîëüêî ïðåäïîëàãàòü, à ýòî âñåãäà ïî÷âà äëÿ ñåêóëÿöèé, êàê è ëþáîé àíàëèç ïîäãðóïï. Âåðîÿòíîñòü ïîëó÷èòü PCI ó ïàöèåíòà áûëà íèæå â ãðóïïå ìåäèêàìåíòîçíîé òåðàïèè 25% vs 115% .  ãðóïïå PCI áîëüøîìó ïðîöåíòó ïîòðåáîâàëàñü âòîðàÿ PCI. Êîðî÷å ãîâîðÿ, ïàèåíòû â èññëåäîâàíèè ïîëíîñòüþ ñîîòâåòñòâóþò òåì, êîòîðûõ ÿ âèæó êàæäûé äåíü â ñâîåé êëèíèêå.
|